RxDoctor Payments Data

Tara Reilly

Nurse Practitioner · San Francisco, CANPI 1710905104

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.8% of the total across 85 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.

$2,246in general payments, 2019–2025

Across 85 payments — averaging $26.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$475
  • AbbVie$413
  • Pfizer$259
  • Lilly USA, LLC$253
  • AstraZeneca$154
  • Viiv Healthcare Company$152
  • plus $541 from 12 others

What the payments were for

  • Food & beverage$2,17397%
  • Education$733%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,246 in reported general payments places this provider in the 85th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$11,900
JardianceEmpagliflozin12$8,216
Estradiol43$2,085
Levothyroxine Sodium92$1,395
Celecoxib18$1,055
ValacyclovirValacyclovir Hcl12$767
Atorvastatin Calcium113$766
Propranolol Hcl ErPropranolol Hcl12$757
Mirtazapine11$619
Losartan Potassium53$584
Rosuvastatin Calcium30$570
Albuterol Sulfate HfaAlbuterol Sulfate19$467
Amlodipine Besylate96$435
Fluticasone Propionate25$421
Omeprazole14$393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$97$11,90012 claims
Boehringer IngelheimJardiance$33$8,21612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →